Patients taking dipeptidyl peptidase4 drugs (DPP4i)a Type 2 diabetes drughad an incidence of acute pancreatitis recurrence of 23.3% versus
GLP-1RA group showed a lower risk at 15.2%. Patients taking dipeptidyl peptidase4 drugs (DPP4i)a Type 2 diabetes drughad an incidence
drugs in patients who are not adherent to conventional OSA treatment. (DPP4i). However, the use of sodium–glucose cotransporter-2
Patients taking dipeptidyl peptidase4 drugs (DPP4i)a Type 2 diabetes drughad an incidence of acute pancreatitis recurrence of 23.3% versus
by A Gravani 2024 Cited by 1Medications in patients with DPP4i associated bullous pemphigoid and in patients without BP despite DPP4i use. Medication. Cohort, n (%) p. OR
by O Varpuluoma 2024 Cited by 49the association between DPP4i medication use and. BP risk.5-7 Currently, it is not known whether DPP4i- associated BP is a drug-induced or
by E D’Andrea 2024 Cited by 43Propensity score distributions of SGLT2i and DPP4i initiators drugs or control medications: a Tennessee Medicaid Study. BMC Med
Multiple antidiabetic formulary alternatives available: metformin, meglitinides (repaglinide, nateglinide), DPP4i's. (Januvia, Tradjenta), GLP1RAs (Trulicity
Dipeptidyl Peptidase-4 Inhibitors (DPP4i) refer to a class of drugs that block the degradation of certain peptides, such as GLP-1 and GIP.
Comments